MediaCo Elevates Key Executives to Propel Multicultural Growth Strategy Across Audio and Video Platforms
NEW YORK--(BUSINESS WIRE)--MediaCo, a leading multimedia company serving multicultural audiences across the United States, today announced key senior leadership appointments aimed at accelerating strategic growth and innovation. Brian Fisher has been promoted to Senior Vice President of Video Sales, Danny Lowry has been promoted to Senior Vice President of Audio Sales, and Luis Fernández-Rocha has been appointed Senior Vice President of Local Video Sales. These executive appointments underscore MediaCo's commitment to expanding its market presence and delivering enhanced value to its partners and audiences.
Brian Fisher – Senior Vice President, Video Sales
Brian Fisher is a proven leader in video sales strategy, instrumental in driving MediaCo's success in the evolving video landscape. He spearheads growth through advertising innovation and strategic revenue development. In his expanded role, Fisher will oversee all video sales across MediaCo's television network and manage streaming video revenue, ensuring a cohesive and forward-thinking strategy across linear and digital platforms. Fisher brings extensive experience from Turner Broadcasting, Bloomberg Media, Tribune Media, and most notably, Disney ABC Television Network, where he spent over a decade helping launch one of the industry's first Full Episode Players, pioneering the transition toward network streaming and shaping today's digital video ecosystem.
Danny Lowry – Senior Vice President, Audio Sales
Danny Lowry is an accomplished executive leader with a distinguished 27-year career in radio and multimedia sales, recognized for his strategic vision, operational excellence, and transformative leadership in multicultural media. Since joining MediaCo in 2019, Danny has significantly elevated the company's audio sales division, initially serving as Director of Sales for Dallas and later expanding his leadership to include Houston. In his current role as Senior Vice President, he drives national sales strategies and fosters strategic partnerships to strengthen MediaCo's position as a leader in the multicultural audio marketplace.
Before MediaCo, Danny held prominent leadership roles at Univision, including General Manager of the Austin market, where he successfully managed all station operations and led notable market growth. He also led Univision's National Radio division, overseeing 62 stations across 16 markets, guiding revenue growth, sales strategy, and operational excellence on a national scale. Throughout his career, Danny has consistently delivered substantial revenue gains and deepened client relationships by blending innovative sales approaches with a deep understanding of multicultural audiences.
Luis Fernández-Rocha – Senior Vice President, Local Video Sales
Luis Fernández-Rocha brings over 30 years of experience in Hispanic media, including two decades in senior leadership roles at TelevisaUnivision. As President and Regional Manager, he successfully led sales operations and drove substantial revenue growth across multiple markets. Fernández-Rocha's extensive expertise in market expansion and strategic partnerships will be instrumental in his role as Senior Vice President of Local Video Sales, where he will guide MediaCo's local television sales initiatives and craft tailored solutions that effectively connect advertisers with multicultural audiences.
'These promotions mark an exciting new chapter for MediaCo,' said Albert Rodriguez, CEO of MediaCo. 'Brian, Danny, and Luis are accomplished leaders who bring passion, expertise, and a deep understanding of the audiences and advertisers we serve. Their leadership will be crucial as we drive the next phase of growth across our audio and video platforms.'
About MediaCo:
MediaCo is a national multimedia company delivering culturally resonant content through television, radio, and digital platforms. Its iconic brands, including WBLS, Hot 97, Don Cheto Radio Network, and top-rated Spanish-language stations in New York, Los Angeles, Dallas, and Houston, reach millions of multicultural consumers each week.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
Wedgewood Pharmacy Adds GS-441524 to Its FIP Treatment Portfolio
SWEDESBORO, N.J., June 05, 2025--(BUSINESS WIRE)--Wedgewood Pharmacy today announced the availability of a GS-441524 formula, a compounded oral antiviral formulation now part of its feline infectious peritonitis (FIP) treatment capabilities. With this addition, veterinarians can now prescribe both GS-441524 and Molnupiravir for their patients, two of the most requested compounded antivirals for FIP, through a single trusted source backed by pharmacist support and FDA-registered ingredient sourcing. GS-441524 can be compounded as a 50mg/ml flavored oral oil suspension in multiple sizes, to improve compliance and ease of administration. The addition complements Wedgewood's Molnupiravir formulations, giving veterinarians access to two antivirals with distinct mechanisms of action. "FIP is one of the toughest diagnoses we face, not just clinically, but emotionally too," said Dr. Rae Hutchins, Chief Veterinary Officer at Wedgewood. "For a long time, vets had to deal with inconsistent access and quality when it came to GS-441524. Now, by offering both GS-441524 and Molnupiravir from one trusted, pharmacist-supported source, we're making it easier for veterinarians to focus on what matters most, giving their patients the best possible chance." "Having access to both GS-441524 and Molnupiravir compounded formulations through Wedgewood not only widens access to affordable FIP treatment across the US, but it also gives veterinarians the ability to easily choose and adapt treatment to best suit the needs of their patients and clients," said Nicole Jacque, co-founder of FIP Global Cats. "Having pharmacists who understand the urgency and complexity of these cases partnering with veterinarians is key to ensuring the best treatment outcomes for cats with FIP." Until recently, many veterinarians relied on fragmented or unregulated sources for GS-441524, making it difficult to ensure consistency and continuity of care. The introduction of this option through Wedgewood reflects a direct response to those challenges, providing prescribers with a trusted, quality-assured formulation from a pharmacy they can count on. The launch of GS-441524 builds on Wedgewood's long-standing role in supporting veterinarians with customized treatment solutions for complex cases. As part of its commitment to responsible compounding, the pharmacy emphasizes that its GS-441524 formulation is not approved by the FDA, has not been studied in clinical trials, and Wedgewood makes no claims of efficacy or safety. Independent third-party studies related to GS-441524 are available for veterinary reference through Wedgewood's FIP Resource Center. To learn more about GS-441524 and access educational resources, visit About WedgewoodWedgewood is the nation's largest and most trusted provider of compounded veterinary medications. Its next-generation home delivery platform, Blue Rabbit, streamlines patient care and marks a significant evolution in online pharmacy services. Together, Blue Rabbit and Wedgewood serve more than 70,000 veterinary professionals and more than one million animals annually. For more information visit About FIP Global Cats FIP Global CATS® (Community, Advocacy, Treatment, Support) is a leading organization in the fight against feline infectious peritonitis (FIP). Uniting veterinarians, researchers, and pet owners, it provides crucial support to those facing an FIP diagnosis. The organization is committed to empowering pet parents, advocating for safe, effective and affordable legal treatments, and advancing FIP research. For more information, please visit View source version on Contacts Jennifer Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
41 minutes ago
- Business Wire
Wedgewood Pharmacy Adds GS-441524 to Its FIP Treatment Portfolio
SWEDESBORO, N.J.--(BUSINESS WIRE)--Wedgewood Pharmacy today announced the availability of a GS-441524 formula, a compounded oral antiviral formulation now part of its feline infectious peritonitis (FIP) treatment capabilities. With this addition, veterinarians can now prescribe both GS-441524 and Molnupiravir for their patients, two of the most requested compounded antivirals for FIP, through a single trusted source backed by pharmacist support and FDA-registered ingredient sourcing. "Having access to both GS-441524 and Molnupiravir compounded formulations through Wedgewood not only widens access to affordable FIP treatment across the US, but it also gives veterinarians the ability to easily choose and adapt treatment." Share GS-441524 can be compounded as a 50mg/ml flavored oral oil suspension in multiple sizes, to improve compliance and ease of administration. The addition complements Wedgewood's Molnupiravir formulations, giving veterinarians access to two antivirals with distinct mechanisms of action. 'FIP is one of the toughest diagnoses we face, not just clinically, but emotionally too,' said Dr. Rae Hutchins, Chief Veterinary Officer at Wedgewood. 'For a long time, vets had to deal with inconsistent access and quality when it came to GS-441524. Now, by offering both GS-441524 and Molnupiravir from one trusted, pharmacist-supported source, we're making it easier for veterinarians to focus on what matters most, giving their patients the best possible chance.' "Having access to both GS-441524 and Molnupiravir compounded formulations through Wedgewood not only widens access to affordable FIP treatment across the US, but it also gives veterinarians the ability to easily choose and adapt treatment to best suit the needs of their patients and clients,' said Nicole Jacque, co-founder of FIP Global Cats. 'Having pharmacists who understand the urgency and complexity of these cases partnering with veterinarians is key to ensuring the best treatment outcomes for cats with FIP.' Until recently, many veterinarians relied on fragmented or unregulated sources for GS-441524, making it difficult to ensure consistency and continuity of care. The introduction of this option through Wedgewood reflects a direct response to those challenges, providing prescribers with a trusted, quality-assured formulation from a pharmacy they can count on. The launch of GS-441524 builds on Wedgewood's long-standing role in supporting veterinarians with customized treatment solutions for complex cases. As part of its commitment to responsible compounding, the pharmacy emphasizes that its GS-441524 formulation is not approved by the FDA, has not been studied in clinical trials, and Wedgewood makes no claims of efficacy or safety. Independent third-party studies related to GS-441524 are available for veterinary reference through Wedgewood's FIP Resource Center. To learn more about GS-441524 and access educational resources, visit About Wedgewood Wedgewood is the nation's largest and most trusted provider of compounded veterinary medications. Its next-generation home delivery platform, Blue Rabbit, streamlines patient care and marks a significant evolution in online pharmacy services. Together, Blue Rabbit and Wedgewood serve more than 70,000 veterinary professionals and more than one million animals annually. For more information visit About FIP Global Cats FIP Global CATS® (Community, Advocacy, Treatment, Support) is a leading organization in the fight against feline infectious peritonitis (FIP). Uniting veterinarians, researchers, and pet owners, it provides crucial support to those facing an FIP diagnosis. The organization is committed to empowering pet parents, advocating for safe, effective and affordable legal treatments, and advancing FIP research. For more information, please visit
Yahoo
an hour ago
- Yahoo
2Modern Welcomes Nicole Andrew as Chief Marketing Officer
MILL VALLEY, Calif., June 05, 2025--(BUSINESS WIRE)--2Modern, a leading retailer for modern design since 2003, proudly announces the appointment of Nicole Andrew as Chief Marketing Officer (CMO). Reporting directly to CEO Greg Finney, Andrew joins the executive leadership team with 17 years in luxury retail & e-commerce marketing and merchandising, including a deep expertise in the design industry. As CMO, Andrew will lead all aspects of marketing, including brand strategy, performance marketing, creative, partnerships, and customer acquisition and retention. Her focus will be on accelerating growth and enhancing the customer experience, marking a pivotal moment as 2Modern enters a new chapter of expansion in the premium design space. Andrew most recently served as Chief Marketing Officer at Perigold, where she played a key role in shaping the brand's identity and driving significant growth over her eight year tenure. Her leadership, strategic vision, and digital expertise helped position Perigold as a standout in luxury e-commerce. "We're thrilled to welcome Nicole to the 2Modern leadership team," said CEO Greg Finney. "Her track record of building strong brands and her deep passion for design make her a perfect fit for our next stage of growth." "I'm incredibly excited to join 2Modern at such a dynamic time," said Andrew. "In just a few weeks, we've already begun reimagining the customer journey, strengthening storytelling across channels, and identifying new opportunities for growth. I've long admired 2Modern's commitment to authentic, elevated design and look forward to building on that legacy." About 2Modern 2Modern is a leading retailer of modern furniture, lighting, and home accessories, dedicated to bringing timeless design into contemporary living spaces. Established in 2003, 2Modern is focused on partnering with iconic and emerging global design brands to inspire customers and elevate interiors through thoughtful, forward-thinking design. For more information, please visit and follow @2modern on Instagram, Facebook, and Pinterest. View source version on Contacts press@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
